Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Patients With Moderate-To-Severe Plaque Psoriasis in Real-World Settings in China
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Psoriasis
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 3506
- Locations
- 2
- Primary Endpoint
- Treatment patterns: Medication dosage
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical needs and disease burden in real-world setting in China.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of moderate-to-severe plaque PsO either confirmed by a dermatologist or meeting criteria of: BSA ≥ 3% or PASI ≥ 3 or Dermatology Life Quality Index (DLQI) ≥ 6.
Exclusion Criteria
- •Participating in Randomized controlled trial (RCT) between 1st January 2018 and 31st December 2021, if there was any.
- •Diagnosis of erythrodermic psoriasis, pustular psoriasis or guttate psoriasis.
Outcomes
Primary Outcomes
Treatment patterns: Medication dosage
Time Frame: Up to 4 Years
Distribution of clinical characteristics: Body Mass Index (BMI)
Time Frame: Baseline
Treatment patterns: Drug names treated during study period
Time Frame: Up to 4 Years
Distribution of clinical characteristics: Weight
Time Frame: Baseline
Distribution of demographic characteristics: Age
Time Frame: Baseline
Distribution of demographic characteristics: Sex
Time Frame: Baseline
Distribution of clinical characteristics: Height
Time Frame: Baseline
Distribution of clinical characteristics: Comorbidities
Time Frame: Baseline
Distribution of clinical characteristics: Disease duration
Time Frame: Baseline
Treatment patterns: Treatment duration of each drug during study period
Time Frame: Up to 4 Years
Distribution of clinical characteristics: Severity of PsO
Time Frame: Baseline
Treatment patterns: Drug categories treated during study period
Time Frame: Up to 4 Years
Treatment patterns: Drug's administration frequency
Time Frame: Up to 4 Years
Treatment patterns: Change of treatment pattern
Time Frame: Up to 4 Years
Treatment patterns: Reason for treatment change during study period
Time Frame: Up to 4 Years
Treatment patterns: Treatment sequence
Time Frame: Up to 4 Years
Secondary Outcomes
- Healthcare resource utilization (HCRU)(Up to 4 Years)
- Number of participants achieving Body Surface Area of <3% during study period(Up to 4 Years)
- Psoriasis Area and Severity (PASI) Index(Up to 4 Years)
- Evaluation of patient reported outcome measure: Patients' global assessment of disease activity (PtGA)(Up to 4 Years)
- Number of participants achieving Static Physicians Global Assessment (sPGA) of 0/1 during study period(Up to 4 Years)
- Evaluation of patient reported outcome measure: Dermatology life quality index (DLQI)(Up to 4 Years)
- Evaluation of patient reported outcome measure: EQ-5D-3L(Up to 4 Years)